T1	Condition 13 25	dyslipidemia
T2	Procedure 107 129	lipid-lowering therapy
T3	Measurement 223 240	total cholesterol
T4	Value 241 254	= 200 mg / dl
R1	Has_value Arg1:T3 Arg2:T4	
T5	Measurement 256 269	triglycerides
T6	Value 270 283	= 180 mg / dl
R2	Has_value Arg1:T5 Arg2:T6	
T7	Measurement 285 300	HDL-cholesterol
T8	Value 301 313	= 40 mg / dl
T9	Measurement 317 332	LDL-cholesterol
T10	Value 333 346	= 150 mg / dl
R3	Has_value Arg1:T9 Arg2:T10	
R4	Has_value Arg1:T7 Arg2:T8	
*	OR T5 T7 T3 T9
T11	Procedure 348 372	Lipid-lowering treatment
T12	Procedure 348 362;377 381	Lipid-lowering diet
T13	Qualifier 383 389	stable
T14	Temporal 390 407	in the last month
R5	Has_temporal Arg1:T13 Arg2:T14	
T15	Condition 174 192	altered analytical
T16	Scope 223 346	total cholesterol = 200 mg / dl, triglycerides = 180 mg / dl, HDL-cholesterol = 40 mg / dl or LDL-cholesterol = 150 mg / dl
R6	Subsumes Arg1:T15 Arg2:T16	
T17	Condition 78 90	dyslipidemia
T18	Scope 78 129	dyslipidemia associated with lipid-lowering therapy
*	OR T18 T15
T19	Scope 78 346	dyslipidemia associated with lipid-lowering therapy. It is also considered patients who have an altered analytical, using the following cutoffs: total cholesterol = 200 mg / dl, triglycerides = 180 mg / dl, HDL-cholesterol = 40 mg / dl or LDL-cholesterol = 150 mg / dl
R7	Subsumes Arg1:T1 Arg2:T19	
T20	Measurement 429 444	LDL-cholesterol
T21	Value 445 462	above 100 mg / dl
R8	Has_value Arg1:T20 Arg2:T21	
T22	Temporal 464 495	in the month prior to inclusion
T23	Reference_point 486 495	inclusion
R9	Has_index Arg1:T22 Arg2:T23	
R10	Has_temporal Arg1:T20 Arg2:T22	
T24	Measurement 501 521	apnea-hypopnea index
T25	Value 522 538	between 5-30 h-1
R11	Has_value Arg1:T24 Arg2:T25	
